Takuaki Yamamoto

Prof. Takuaki Yamamoto

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
JHJeremy T. Hines
Jeremy T. Hines
WJWoo-Lam Jo
Woo-Lam Jo
QCQuanjun Cui
Quanjun Cui
MMMichael A. Mont
Michael A. Mont
KKKyung-Hoi Koo
Kyung-Hoi Koo
JPJung-Wee Park
Jung-Wee Park
Hines JT, et al. J Korean Med Sci. 2021 May;36(24):e177. https://doi.org/10.3346/jkms.2021.36.e177

1 January 2021 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
QCQuanjun Cui
Quanjun Cui
WJWoo-Lam Jo
Woo-Lam Jo
KKKyung-Hoi Koo
Kyung-Hoi Koo
ECEdward Y. Cheng
Edward Y. Cheng
WDWolf Drescher
Wolf Drescher
DZDewei Zhao
Dewei Zhao
Cui Q, et al. J Korean Med Sci. 2021 Feb;36(10):e65. https://doi.org/10.3346/jkms.2021.36.e65

Verified
Journal Article
Open access
PDF file
JNJun Nishio
Jun Nishio
SNShizuhide Nakayama
Shizuhide Nakayama
KNKazuki Nabeshima
Kazuki Nabeshima
TYTakuaki Yamamoto
Takuaki Yamamoto
Dedifferentiated liposarcoma (DDL) is defined as the transition from well-differentiated liposarcoma (WDL)/atypical lipomatous tumor (ALT) to non-lipogenic sarcoma, which arises mostly in the retroperitoneum and deep soft tissue of proximal extremities. It is characterized by a supernumerary ring and giant marker chromosomes, both of which contain amplified sequences of 12q13-15 including murinedouble minute 2 (MDM2) and cyclin-dependent kinase 4 (CDK4) cell cycle oncogenes. Detection of MDM2 (and/or CDK4) amplification serves to distinguish DDL from other undifferentiated sarcomas. Recently, CTDSP1/2-DNM3OS fusion genes have been identified in a subset of DDL. However, the genetic events associated with dedifferentiation of WDL/ALT remain to be clarified. The standard treatment for localized DDL is surgery, with or without radiotherapy. In advanced disease, the standard first-line therapy is an anthracycline-based regimen, with either single-agent anthracycline or anthracycline in combination with the alkylating agent ifosfamide. Unfortunately, this regimen has not necessarily led to a satisfactory clinical outcome. Recent advances in the understanding of the pathogenesis of DDL may allow for the development of more-effective innovative therapeutic strategies. This review provides an overview of the current knowledge on the clinical presentation, pathogenesis, histopathology and treatment of DDL.

10 February 2022 in The Journal of Arthroplasty
Verified
Journal Article
Closed access
KKKyung-Hoi Koo
Kyung-Hoi Koo
MMMichael A. Mont
Michael A. Mont
QCQuanjun Cui
Quanjun Cui
JHJeremy T. Hines
Jeremy T. Hines
BYByung-Ho Yoon
Byung-Ho Yoon
HKHong-Seok Kim
Hong-Seok Kim

8 November 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YSYuma Sakamoto
Yuma Sakamoto
TYTakuaki Yamamoto
Takuaki Yamamoto
NSNobuhiko Sugano
Nobuhiko Sugano
DTDaisuke Takahashi
Daisuke Takahashi
TWToshiyuki Watanabe
Toshiyuki Watanabe
SIShiro Ikegawa
Shiro Ikegawa
Idiopathic osteonecrosis of the femoral head (IONFH) is an ischemic disorder that causes bone necrosis of the femoral head, resulting in hip joint dysfunction. IONFH is a polygenic disease and steroid and alcohol have already known to increase its risk; however, the mechanism of IONFH remains to be elucidated. We performed a genome-wide association study using ~60,000 subjects and found two novel loci on chromosome 20q12 and 12q24. Big data analyses identified LINC01370 as a candidate susceptibility gene in the 20q12 locus. Stratified analysis by IONFH risk factors suggested that the 12q24 locus was associated with IONFH through drinking capacity. Our findings would shed new light on pathophysiology of IONFH.

21 May 2020 in Journal of Back and Musculoskeletal Rehabilitation
Verified
Journal Article
Closed access
PDF file
NKNaoya Kotani
Naoya Kotani
TMTakashi Morishita
Takashi Morishita
KSKazuya Saita
Kazuya Saita
SKSatoshi Kamada
Satoshi Kamada
AMAkira Maeyama
Akira Maeyama
TITooru Inoue
Tooru Inoue
BACKGROUND: The Hybrid Assistive Limb (HAL) is a robotic exoskeleton designed to support impaired limbs. OBJECTIVE: We aimed to evaluate whether active exercise using a single-joint HAL (HAL-SJ) following total knee arthroplasty can facilitate the re